Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



From the category archives: OBN News

Company announcement

Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary

Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer

Read the rest of entry »

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus.

Read the rest of entry »

Leading biotech Immunocore expands to The Oxford Science Park

Oxford, UK:  Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford

Read the rest of entry »

Wessex Academic Health Science Network and Wessex Clinical Research Network launch their Technology Support Programme (Round 1)

Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products.  Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.

Read the rest of entry »

Oxford MEStar wins grant support to work with CGT Catapult and AK Biomedical as part of Jiangsu-UK industrial challenge programme

Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.

Read the rest of entry »

Summit Therapeutics to Report Financial Results for the Third Quarter And Nine Months Ended 31 October 2017 On 6 December 2017

Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017. About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Summit     Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 ...

Read the rest of entry »

Activate Science has been all over Europe

Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 28 customer sites in 2017.

Read the rest of entry »

Isansys travels with NASA to Antarctica

NASA to evaluate the use of Isansys’ physiological monitoring tools to learn how to monitor explorers as they travel into space.  A NASA exploration scientist set off on his mission to Antarctica being monitored by the Patient Status Engine, a physiological data collection platform which provides monitoring of individuals wirelessly and in real-time.

Read the rest of entry »

MSD announces plan to establish UK Discovery Centre in London

MSD, known as Merck and Co., Inc., in the US and Canada, has today announced its commitment to establish a state of the art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation

Read the rest of entry »

Arecor Strengthens the Patent Portfolio of its Formulation Technology for the Development of Novel Vaccine and Gene Therapy Products

Notification of an ‘intention to grant’ patent protecting Arecor’s novel approach to enabling stable liquid adenovirus formulations, has been received from both the European and US patent offices. 

Read the rest of entry »

Pages: Previous1234567...11NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.